Dianthus Therapeutics (DNTH) Depreciation & Amortization (CF) (2017 - 2025)

Dianthus Therapeutics' Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $27000.0 for Q3 2025.

• On a quarterly basis, Depreciation & Amortization (CF) rose 8.0% year-over-year to $27000.0 in Q3 2025; TTM through Dec 2025 was $84000.0, a 12.5% decrease from a year earlier, with the FY2024 full-year figure at $96000.0, up 43.28% from the prior year.
• Depreciation & Amortization (CF) eased to $27000.0 in Q3 2025 per DNTH's latest filing, from $30000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $532000.0 in Q3 2021 and bottomed at $19000.0 in Q3 2023.
• The 5-year median for Depreciation & Amortization (CF) is $225500.0 (2023), against an average of $253611.1.
• Across the five-year window, Depreciation & Amortization (CF) slumped 95.97% in 2023 and surged 31.58% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $515000.0 in 2021, then declined by 9.51% to $466000.0 in 2022, then tumbled by 95.71% to $20000.0 in 2023, then rose by 30.0% to $26000.0 in 2024, then climbed by 3.85% to $27000.0 in 2025.
• Per Business Quant, the three latest DNTH Depreciation & Amortization (CF) figures stand at $27000.0 (Q3 2025), $30000.0 (Q2 2025), and $27000.0 (Q1 2025).